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Abstract In order to obtain insights into the methicillin-
resistant Staphylococcus aureus (MRSA) population struc-
ture in the Azores archipelago, 106 MRSA isolates were
collected from patients attending an Azorean central
hospital between January 2007 and February 2008. Anti-
microbial resistance was determined for all isolates.
Molecular typing was performed by pulsed-field gel
electrophoresis (PFGE), spa typing, multilocus sequence
typing (MLST), staphylococcal chromosome cassette mec
(SCCmec) typing and the presence of Panton–Valentine
leukocidin (PVL). The majority of the isolates (87%, n=92)
belonged to the EMRSA-15 clone (ST22, SCCmec-IVh),
followed by the Pediatric clone (ST5-VI/IVc) (11%, n =1 2 ) .
The Berlin clone (ST45-IVa) and a new clone (spa type
t1839, ST1339 and SCCmec V variant) were represented by
single isolates. All of the isolates carried SCCmec types IV,
V or VI and a non-multiresistant antibiotic profile, resem-
bling the currently emerging community MRSA. Moreover,
PVL was described for the first time to be associated with the
Pediatric clone carrying SCCmec type VI. We provided the
first description of the population structure of MRSA in the
Azores islands, which seems to be shaped by genetic events
occurring locally, as well as by the regular population
exchange between the islands, continental Portugal, the
United Kingdom and the United States.
Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) is a
major pathogen associated with both nosocomial- and
community-acquired infections (hospital-acquired [HA]
MRSA and CA-MRSA, respectively) [1]. MRSA are
believed to have emerged by the acquisition of the
staphylococcal cassette chromosome mec (SCCmec), the
mobile genetic element carrying the determinant of methi-
cillin resistance (mecA) into methicillin-susceptible S. aureus
(MSSA). Eight different SCCmec types (I to VIII) have been
described so far in S. aureus, differing in their structure and
size. Epidemiological studies using molecular typing meth-
ods showed that the massive geographical spread of MRSA
in hospitals results from the dissemination of a few highly
epidemic clones. These major epidemic clones resulted from
a limited number of independent acquisitions of SCCmec
into well-defined genetic backgrounds: (i) New York/Japan
clone, sequence type (ST) 5, SCCmec II; (ii) Pediatric clone,
ST5-IV/VI; (iii) Brazilian clone, ST239-III/IIIA; (iv) Iberian
clone, ST247-IA; (v) EMRSA-15, ST22-IV; (vi) EMRSA-
16, ST36-II; and (vii) Berlin clone, ST45-IV [2–4].
The MRSA prevalence in European hospitals varies
from less than 3.0% in the Nordic Countries and The
Netherlands to over 50% in southern European countries
and the United Kingdom. Despite the significant decrease
in MRSA incidence in a few countries (France, Slovenia,
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control, the incidence has increased in other countries,
including Portugal, where the MRSA proportion is, nowa-
days, over 50%, being one of the highest in Europe [1, 5].
Surveillance studies have been conducted in Portugal
since the early 1990s, showing temporal waves of MRSA
clonal prevalence. In the most recent survey conducted in
2006, EMRSA-15 (ST22-IVh) was found to be the most
prevalent clone in Portuguese hospitals, followed by the
New York/Japan clone (ST5-II) [5, 6].
Information about the epidemiology of CA-MRSA is still
scarce and non-existent in Portugal. Unlike HA-MRSA, CA-
MRSA are usually only resistant to beta-lactams and one or
two additional antimicrobial classes, and carry mainly
SCCmec types IV and V, the smallest in size, which are
believed to be more mobile. CA-MRSA frequently harbour
Panton–Valentine leukocidin (PVL), but the toxin has also
been detected in the hospital environment [7, 8]. Similarly to
HA-MRSA, CA-MRSA epidemic clones have been de-
scribed [9]. However, a much larger genetic diversity in the
genetic backgrounds of CA-MRSA has been observed,
suggesting a high number of SCCmec acquisitions in the
community. Recent data indicates that MRSA epidemiology
is suffering a new change and that the boundaries between
the hospital and the community are blurring. As a result,
clones traditionally linked to the hospital, like the EMRSA-
15 clone, were found to be aetiologic agents of infection in
the community [10] and clones specific to the community
were observed as causing infections in hospitals, as is the
case of the USA300 strain [11, 12]. A common trait to these
clones that can survive in both environments appears to be
the presence of SCCmec type IV that is, nowadays, prevalent
among the current overall MRSA population [5, 6, 13–15].
Whereas the epidemiology of nosocomial MRSA has
been very well characterised in the Portuguese continental
territory, there is no information concerning the prevalence
and clonality of MRSA in the Portuguese islands, namely
in the Azores archipelago.
The aim of the present study was to identify the MRSA
clonal types currently circulating in the Azores archipelago
and compare them with the major MRSA clones described
in continental Portugal, Europe and the United States.
Materials and methods
Hospital setting
Hospital do Divino Espírito Santo (HDES) is a 390-bed
central hospital located in Ponta Delgada, São Miguel
island, that services an outpatient population of 138,000
inhabitants, from the two most populous Azorean islands,
S. Miguel and Santa Maria. The hospital, the largest in the
archipelago, includes medicine and surgery as principal
wards, and a large outpatient ambulatory unit.
Bacterial isolates
Between January 2007 and February 2008, a total of 106
MRSA isolates were collected from both inpatients (n=93,
87.7% of the isolates) and outpatients (n = 13, 12.3% of the
isolates) attending HDES. The collection included single-
patient isolates recovered from several sources, including
sputum (n=35, 33%), urine (n = 22, 21%), swabs from
various origins (n = 19, 18%), exudates from wounds, one
abscess and one ear infection (n = 16, 15%), blood (n = 10,
9.5%), catheters (n = 2, 1.9%) and auricular and peritoneal
fluids (n = 1, 0.9% each). Most of the isolates (95%, n =
101) were from infection. The majority of the patients
(73.5%) were inpatients hospitalised in three wards:
medicine (n=42, 39.6%), surgery (n = 24, 22.6%) and
pneumology (n = 12, 11.3%). Among the 13 outpatients,
three attended the haemodialysis unit.
Antimicrobial susceptibility testing and mecA detection
Susceptibility testing was performed with the semi-
automatic Vitek system (bioMérieux, SA, France) accord-
ing to the manufacturer’s instructions for a panel of 12
antibiotics: ciprofloxacin, clindamycin, erythromycin,
gentamicin, linezolid, oxacillin, penicillin, rifampicin,
trimethoprim-sulfamethoxazole, teicoplanin, tetracycline
and vancomycin. Bacterial isolates were considered to
belong to different antibiotypes if at least one difference
was observed in the antibiotic resistance profile.
The presence of the mecA gene was confirmed in all
oxacillin-resistant isolates by polymerase chain reaction
(PCR) [16].
PFGE
Pulsed-field gel electrophoresis (PFGE) was performed as
described by Chung et al. [17] on all 106 isolates. The
resulting SmaI restriction patterns were analysed by both
visual inspection using the criteria of McDougal et al. [18]
and automatically with the BioNumerics software version
4.61 (Applied Maths, Sint-Martens-Latem, Belgium). Den-
drograms were generated as previously described [19] using
an optimisation of 0.50% and a tolerance of 1.25%. A
similarity coefficient of 80% was used to define the PFGE
type clusters [19].
spa typing and MLST
spa typing was carried out on at least one representative of
each PFGE subtype (n = 26) and spa types were assigned
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[20]. Multilocus sequence typing (MLST) was conducted as
described [21] for selected strains previously typed by PFGE
and spa typing. The allelic profiles and sequence types (ST)
were defined using the MLST database (http://www.mlst.net).
SCCmec and ccr typing
SCCmec was typed by the multiplex PCR strategy
described by Milheiriço et al. [22]. Additionally, all type
IV isolates were further subtyped as previously described
[23]. Type VI isolates were confirmed by amplification of
the cassette chromosome recombinase genes ccrAB4 [24].
Type V was confirmed by PCR amplification of ccrC and
mec complex C, as previously described [16, 25]. Non-
typeable isolates by the methods mentioned above were
characterised by ccrB sequencing [26].
PVL detection
All 106 MRSA isolates were screened for the presence of
PVL lukS/lukF genes by PCR, as described previously [27].
Positive results were confirmed by sequencing of the PCR
amplicon.
Results
Antimicrobial susceptibility
The 106 isolates were assigned to eight different antibio-
types (Table 1) with a prevalent non-multiresistant pattern.
The majority of the isolates (n=91, 85.9%) showed
antibiotype 1 (resistance to oxacillin, penicillin, ciproflox-
acin and erythromycin) or 2 (resistance to oxacillin,
penicillin and ciprofloxacin). The isolate with antibiotype
7 was unique in showing resistance to gentamicin. Anti-
biotype 8, which showed resistance to six different
antimicrobials, included a single isolate.
All 106 isolates harboured the mecA gene and, therefore,
were classified as MRSA.
Predominance of EMRSA-15 clone
The characterisation of the 106 MRSA strains by PFGE,
spa typing, MLST and SCCmec typing clustered the
isolates into four clonal types (Fig. 1). The majority of the
isolates (n=92, 87%) belonged to PFGE type A. PFGE type
B included 11% (n = 12) of the isolates and types C and D
were represented by single isolates only (1% each).
PFGE type A was subdivided into nine subtypes;
subtypes A1 (n=40) and A2 (n = 22) represented 67% of
all type A isolates. The representative isolate of PFGE type
A (subtype A1) showed spa type t032, ST22 and SCCmec
type IVh, which are characteristics of the internationally
disseminated EMRSA-15 clone [28]. Interestingly, subtype
A4 showed the same restriction profile as the EMRSA-15
clone reference strain, HAR22, but a different spa type
(t032), including one additional repeat sequence (Fig. 1).
All representative isolates of type A shared the same spa
type t032, except one isolate (t910), which differs from
t032 by the deletion of five repeats. HDES85 was the
unique isolate of PFGE type A1 defined as non-typeable by
spa typing, since no PCR product was obtained. Another
Table 1 Resistance profile of the 106 methicillin-resistant Staphylococcus aureus (MRSA) isolates and associated pulsed-field gel electrophoresis
(PFGE) types
Antibiotype Resistance profile
a Total no. of
isolates (%)
PFGE types
(subtypes)
OXA PEN CIP ERY CLI RIF GEN LZD SXT TEC TET VAN
1 RR R R S S S S S S S S 67 (63.2) A (1–9);
B (1, 2); D (1)
2 RR R S S S S S S S S S 24 (22.7) A (1–6);
B (1, 4); C (1)
3 RR S R S S S S S S S S 7 (6.6) A (1, 2, 5);
B (1)
4 RR R R R S S S S S S S 3 (2.8) A (1)
5 RR S S S S S S S S S S 2 (1.9) A (4); B (3)
6 RR R SS R S S S S S S 1 (0.9) A (1)
7 RR SS IR RS S S S S 1 (0.9) B (1)
8 RR R R R R S S S S S S 1 (0.9) B (1)
aS, susceptible; I, intermediate; R, resistant
Antibiotic abbreviations: OXA, oxacillin; PEN, penicillin; CIP, ciprofloxacin; ERY, erythromycin; CLI, clindamycin; RIF, rifampicin; GEN,
gentamicin; LZD, linezolid; SXT, trimethoprim-sulfamethoxazole; TEC, teicoplanin; TET, tetracycline; VAN, vancomycin
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cassette type IV non-subtypeable. PFGE type A included
isolates from six out of the eight antibiotypes described, but
95% (n=53) of the isolates belonged to antibiotypes 1 and
2 (Table 1).
Evidence of horizontal gene transfer among strains
of the Pediatric clone
PFGE type B was the second most common PFGE type and
included three subtypes, of which B1 represented 75% (n=9)
of type B isolates (Fig. 1). Subtypes B1 and B2 showed ST5,
SCCmec VI and spa types t062, t2049, t2724 (B1)/t311
(B2), which are typical of the Pediatric clone. SCCmec type
VI was confirmed in five isolates by amplification of the
characteristic ccrAB4 genes. The remaining type VI isolates
did not amplify the ccrAB4 genes by uniplex PCR but
showed a ccrB sequence with 100% homology with the
Pediatric clone reference strain HDE288 [29]. Interestingly,
subtype B3 carried SCCmec type IVc instead of the SCCmec
type VI, which may indicate the occurrence of independent
acquisition of SCCmec in the Pediatric clone background.
Moreover, we found that three isolates belonging to
PFGE subtype B1 (ST5-VI) carried the PVL genes.
The remaining two isolates belonged to PFGE types C
and D and were, respectively, recovered from an outpatient
and an inpatient. PFGE C isolate, spa type t004 and ST45-
IVa showed a single band difference relative to HAR38, the
prototype isolate of the Berlin clone (spa type t004, ST45-
IVa) [30, 31]. PFGE type D isolate showed spa type t1839,
a novel sequence type (ST1339) not related to any major
clonal complex (CC) and a variant of SCCmec type V.
High genetic diversity and high frequency of SCCmec
types IV, V and VI
SCCmec type IV was found to be the prevalent type (n =
13) among the 24 isolates tested. Three different SCCmec
IV subtypes were found in this collection, associated to
three unrelated genetic backgrounds (ST5: SCCmec IVc,
ST22: SCCmec IVh/IVnon-subtypeable, and ST45:
SCCmec IVa). SCCmec type VI was the second most
prevalent cassette type, which appeared to be associated to
isolates with PFGE types B1 and B2. A variant of SCCmec
type V was shown on a single isolate that harboured the
mec complex C and ccrC genes, but missed the specific
type V J1 region. No isolates carrying SCCmec types I, II
or III were identified in this collection.
Discussion
In order to describe the MRSA population structure in the
Atlantic Azores islands, a collection of 106 isolates
recovered during a 13-month period was characterised by
a combination of up-to-date molecular typing methods. The
analysis showed the predominance of two major interna-
tional MRSA clones: the EMRSA-15 clone and the
Pediatric clone.
Massive dominance of the EMRSA-15 clone
In the present study, 87% of the isolates showed molecular
characteristics of the highly internationally disseminated
EMRSA-15 clone (ST22-IVh) [28], including a common
Strain PFGE spa  type SCCmec PVL Antibiotype ST
0
0
0
0
0
0
type type
1
9
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7
0
6
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t032
IVh
IVh
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1
.
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1
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.
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Fig. 1 Molecular characterisation of representative methicillin-resistant Staphylococcus aureus (MRSA) isolates of each pulsed-field gel
electrophoresis (PFGE) subtype and comparison with MRSA pandemic clones
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showed t910, a spa type already reported in a CC22 isolate
from Germany [32]. This fact is not surprising, since the
spa gene is a variable repeat region prone to the
introduction or deletion of repeats. Regional spa clusters
frequently include highly related spa types characterising
clonal related isolates, which translates a local evolution of
the spa locus [8, 33]. Unusually, a non-typeable isolate was
found in the collection, which should be due to a mutation
or insertion/deletion in spa rather than non-existence of the
gene [34]. Interestingly, the majority of the EMRSA-15
isolates described in this study were recovered from sources
other than blood (sputum, swabs, exudates and urine),
corresponding to the major pathologies presented by the
patients attending HDES (respiratory tract and skin related).
The non-multiresistant EMRSA-15 clone emerged in the
United Kingdom in 1991 and rapidly became a dominant
clone worldwide, particularly in Europe [8, 35]. Recently,
an EMRSA-15 variant was reported in central United States
[36]. In the Azores islands, the clear dominance of the
EMRSA-15 clone is, in part, in agreement with the
situation in continental Portugal [5, 6]. In fact, in a study
involving isolates recovered in the same period from 11
hospitals scattered over continental Portugal, EMRSA-15
was found to be the most prevalent clone. However, and in
contrast with the present study, the New York/Japan clone
(ST5-II) was shown to represent a new wave of MRSA in
the country, whereas the Pediatric clone (ST5-VI/IV) was
exceedingly rare [5]. In the Portuguese neighbouring
country Spain, EMRSA-15 was found in continental
territory in co-existence with EMRSA-16 and two CC5
clones (ST125-IV and ST146-IV), but not as a major clone
as in the Spanish islands (Majorca and Canarias) and as in
our study [14, 37, 38]. The frequent touristic flux from the
United Kingdom, hypothesised as the cause of the
importation of EMRSA-15 to the Mediterranean island of
Malta [39], could also support, in part, the emergence of
this clone in the most touristic Azores islands. In parallel,
the regular exchange of inhabitants between the islands and
the continent seem to be an important vehicle of clonal
importation.
Emergence of PVL and SCCmec variability: evidence
for local evolution
Recent studies revealed that the Pediatric MRSA clone,
isolated for the first time in 1992 in a Portuguese hospital
[29], was no longer present in that hospital in 2006 [5].
However, it appeared in the present collection as the second
major clone.
Interestingly, in this study, we observed that strains of
the Pediatric clone differing in three to five bands in PFGE
pattern, isolated in the same hospital, carried either the
typical SCCmec types VI or IVc. ST5-VI MRSA isolates,
which had been restricted to isolates from continental
Portugal, were recently found in a collection of nosocomial
isolates recovered from 23 hospitals located throughout
France [24, 40]. The hypothesis of a recent introduction of
this clone from continental Portugal seems to be quite
remote, since, in a recent national study, this clone was
isolated from a single patient only in a hospital in the South
of Portugal [5]. On the other hand, the Azores islands have
a high emigrant community in the United States, who
frequently travel to the national territory, constituting also
possible vehicles of dissemination of the Pediatric clone
strains already reported in this country.
ST5 lineage is known to frequently acquire mobile
genetic elements, such as different SCCmec, antibiotic
resistance and toxin genes [4, 41]. In a recent study, Nübel
et al. showed that at least 23 SCCmec acquisitions events
have occurred within ST5 lineage, on multiple and
independent occasions, showing evidence that the MRSA
emerged in numerous circumstances and in distinct loca-
tions rather than by the geographic dispersal of isolates [4].
Moreover, besides being originally identified in a
community-associated USA400 strain, the first introduction
of SCCmecIV in S. aureus might have occurred in the ST5
Pediatric clone background that was circulating in hospitals
in the 1990s [9]. Similarly, our results suggest that SCCmec
cassettes VI and IVc might have been introduced de novo
and recently in these ST5 strains and that the Pediatric
clone may be evolving locally. Another observation that
supports the hypothesis of recent local evolution of the
Pediatric clone is the presence of PVL-positive and PVL-
negative strains with closely related PFGE profiles. Note-
worthy, this is the first report of PVL among isolates
belonging to the SCCmec type VI Pediatric clone. The
introduction of the PVL genes in a genetic background with
such a high epidemic potential is of particular concern.
However, we cannot exclude the reverse hypothesis of a
local evolution through the acquisition of SCCmec type VI
by a PVL-positive MSSA. Only the analysis of the genetic
background of susceptible S. aureus in the Azores islands
would clarify the chronological acquisition of PVL and
SCCmec in these Pediatric clone strains.
The Berlin MRSA clone (ST45-IVa), first observed in
Berlinhospitals in1993,iscurrently spreadinsomeEuropean
countries [8, 42], showing a high epidemic potential not only
in the hospital environment but also in the community [43,
44]. This clone was found in a single MRSA isolate in the
Azores island collection. The same genetic background
(ST45) had been previously described in Portuguese hospi-
tals, but exclusively among MSSA isolates [45]. The
collection of a single MRSA isolate carrying SCCmec IVa
suggests another de novo SCCmec acquisition, probably in
an already established MSSA clone.
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V seems to have occurred in an isolate with spa type t1839
and a novel sequence type (ST1339) that is a singleton.
This strain is not related to the single SCCmec type V
variant isolate (ST45) previously reported in Portugal [5].
Interestingly, this isolate was recovered from a patient
within the first 48 h of hospitalisation, from a skin and soft
tissue infection (erysipelas), the main source of CA-MRSA
isolates. However, the isolate could not be considered as
having a community origin, since no additional information
regarding patient risk factors was available.
Emergence of HA-MRSA isolates with community traits
SCCmec type IV is one of the most frequent SCCmec types
found in the community and is, nowadays, becoming the
predominant type also in the nosocomial setting [5, 6, 9,
13–15, 46]. Moreover, this SCCmec type has been usually
associated to a pattern of susceptibility to almost all
antimicrobial classes. These same characteristics were
observed in isolates from our study: SCCmec type IV was
found to be the most frequent SCCmec type and all isolates
were highly susceptible. At least three different SCCmec
subtypes were identified (IVh: EMRSA-15, IVc: Pediatric
clone, IVa: Berlin clone), showing evidence of a high
genetic diversity among the pool of SCCmec type IV in the
Azores islands. Interestingly, the detection of one isolate
belonging to the EMRSA-15 clone, SCCmec type IV non-
subtypeable (only positive for the ccrB2 allele in the
subtyping multiplex), suggests the presence of a new
uncharacterised SCCmec type IV subtype in addition to
the ones already described [23].
Besides SCCmec type IV, the only SCCmec types found
among the whole collection were the small SCCmec V and
VI, reflecting the actual tendency for the dominance of low
resistant and fitness cost clones within the hospital setting,
which is parallel with what is observed in the community
environment [9]. The introduction of well-established
community isolates into the hospital setting is not new, as
observed in Taiwan, where the ST59 clonal type, highly
prevalent in the community, emerged in the hospital setting
as the second most prevalent clone [38, 47, 48]. Although
ST22-IV EMRSA-15-related isolates as well as ST5-IV
were already reported in the community [10, 46], no
conclusions can be drawn for the flow direction in the
present study. Even if a high percentage (30%) of the
isolates studied was recovered within the first 48 h of
admission or in an outpatient unit, no data of previous
hospital contact was available for the patients.
In the present study, we provided the first description of
the population structure of MRSA in the Azores islands and
showed a prevalence of the epidemic EMRSA-15 clone in
co-existence with the Pediatric clone. Our findings were in
line with recent reports from continental Portuguese and
European hospitals. The horizontal gene transfer and the de
novo acquisition of mobile genetic elements seem to have
contributed to the local genetic diversity and clonal
evolution. Moreover, the population exchange between the
islands and continental Portugal or the United States, in
addition to the high flux of tourists, particularly from the
United Kingdom, may explain the dominance and spread of
the EMRSA-15 and Pediatric clones. Further surveillance
studies concerning both HA-MRSA and MSSA populations
and CA-MRSA in the geographically restricted Azores
islands will be fundamental to support the S. aureus
localised evolution, as well as to understand the links
between the hospital and the community.
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